| Literature DB >> 32912361 |
Susu Ye1, Xinlei Zhang2, Yu Bao Zhang3, Xintao Tian3, Ailing Liu4, Changxing Cui3, Lei Shi3, Di Xia3.
Abstract
TLR3 and IL-10 play a crucial role in antiviral defence. However, there is a controversy between TLR3 rs3775291 and IL-10 rs1800871 polymorphisms and the risk of hepatitis B virus (HBV) infection. The purpose of this study is to explore the relationship between the two single nucleotide mutations and the risk of HBV infection by meta-analysis. Medline, EMBASE, Web of Science, CNKI, China Wanfang database were searched for the case-control studies on the relationship between TLR3 rs3775291 and IL-10 rs1800871 polymorphism and susceptibility to HBV, updated to June 2020. The data were analysed by Stata 15.0 software. A total of 22 articles were included. The results showed that in the analysis of IL10 rs1800871 polymorphism and the risk of HBV infection, the pooled OR was 1.21 (95% CI 1.06-1.37), 1.28 (95% CI 1.04-1.56) and 1.20 (95% CI 1.06-1.37) and 1.40 (95% CI 1.07-1.83) in the allele model (C vs. T), dominant model (CC+CT vs. TT), recessive model (CC vs. CT+TT) and homozygous model (CC vs. TT), respectively. There was no statistical significance in the heterozygote model. A subgroup analysis of the Asian population showed similar results. The analysis of TLR3 rs3775291 polymorphism and the risk of HBV showed that in the allele model (T vs. C), the pooled OR was 1.30 (95% CI 1.05-1.61). Except for the recessive model, no significances were found in other genetic models. In conclusion, TLR3 rs3775291 and IL-10 rs1800871 polymorphisms are associated with the risk of HBV. Allele C and genotype CC at IL10 rs1800871 loci, as well as allele T and genotype TT at TLR rs3775291 loci, may increase susceptibility to Hepatitis B infection.Entities:
Keywords: Hepatitis B virus; Interleukin 10; Toll-like receptor 3; meta-analysis; polymorphism
Year: 2020 PMID: 32912361 PMCID: PMC7557109 DOI: 10.1017/S0950268820002101
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Fig. 1.Screening flow diagram for inclusion in the study.
Basic characteristics of the studies on the correlation between TLR3 rs3775291 polymorphism and HBV
| First author | Year | Country | Control source | HBV | Control | NOS score | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TT | CT | CC | TT | CT | CC | ||||||
| Li GG | 2013 | China | H | 41 | 174 | 133 | 11 | 48 | 59 | 0.785 | 8 |
| Rong YH | 2013 | China | H | 42 | 212 | 198 | 23 | 189 | 250 | 0.091 | 8 |
| Sá | 2015 | Brasil | H | 3 | 18 | 26 | 33 | 132 | 134 | 0.954 | 8 |
| Chen DN | 2017 | China | S | 45 | 150 | 97 | 92 | 323 | 271 | 0.784 | 8 |
| Fischer | 2018 | German | S | 137 | 236 | 248 | 23 | 92 | 124 | 0.332 | 8 |
HBV, Hepatitis b virus; H, healthy controls; S, self-limiting infection controls; HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa Scale.
Basic characteristics of the studies on the correlation between IL10 rs1800871 polymorphism and HBV
| First author | Year | Country | Control source | HBV | Control | NOS score | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | CT | TT | CC | CT | TT | ||||||
| Miyazoe | 2002 | Japan | H | 27 | 91 | 95 | 6 | 20 | 26 | 0.483 | 8 |
| Li C | 2006 | China | H | 23 | 81 | 78 | 8 | 21 | 34 | 0.119 | 8 |
| Zhang PA | 2006 | China | H | 25 | 103 | 103 | 12 | 67 | 56 | 0.199 | 7 |
| Xie HY | 2008 | China | H | 15 | 93 | 78 | 10 | 68 | 73 | 0.266 | 8 |
| Truelove a | 2008 | African-Americans | S | 18 | 23 | 4 | 24 | 37 | 15 | 0.914 | 8 |
| Truelove b | 2008 | European-Americans | S | 109 | 60 | 10 | 182 | 112 | 19 | 0.750 | 8 |
| Yan Z | 2009 | China | H | 120 | 428 | 531 | 33 | 150 | 231 | 0.219 | 8 |
| Liu JJ | 2010 | China | H | 36 | 200 | 183 | 20 | 92 | 75 | 0.292 | 8 |
| Qiu XQ | 2011 | China | H | 538 | 406 | 117 | 181 | 143 | 35 | 0.389 | 8 |
| Wang S | 2011 | China | H | 4 | 12 | 36 | 4 | 12 | 33 | 0.085 | 8 |
| Wang CJ | 2011 | China | H | 33 | 168 | 134 | 18 | 71 | 76 | 0.817 | 7 |
| Sodsai | 2012 | Thailand | H | 10 | 74 | 47 | 16 | 59 | 67 | 0.584 | 8 |
| Wang C | 2012 | China | H | 12 | 34 | 16 | 69 | 251 | 205 | 0.567 | 8 |
| Sofian | 2013 | Iran | H | 45 | 43 | 12 | 16 | 11 | 4 | 0.358 | 8 |
| Srivastava | 2014 | India | H | 68 | 111 | 53 | 9 | 29 | 38 | 0.352 | 8 |
| Talaat | 2014 | Egypt | H | 69 | 40 | 6 | 62 | 52 | 5 | 0.143 | 8 |
| Chen W | 2018 | China | H | 39 | 72 | 104 | 11 | 63 | 46 | 0.106 | 7 |
| Rybicka | 2020 | France | S | 182 | 106 | 32 | 6 | 10 | 8 | 0.431 | 8 |
HBV, Hepatitis b virus; H, healthy controls; S, self-limiting infection controls; HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa Scale.
Main results of meta-Analysis of HBV susceptibility to TLR3 rs3775291 Polymorphisms
| Genetic model | OR | 95% CI | I2 | Statistical models | ||||
|---|---|---|---|---|---|---|---|---|
| Allelic model | 5 | 1.3 | 1.05–1.61 | 0.014 | 69.6 | 0.011 | REM | 0.457 |
| Dominant model | 5 | 1.42 | 1.23–~1.65 | 0.000 | 47.5 | 0.107 | FEM | 0.280 |
| Recessive model | 5 | 1.53 | 1.00–2.34 | 0.051 | 62.8 | 0.029 | REM | 0.727 |
| Homozygous model | 5 | 1.74 | 1.11–2.73 | 0.016 | 63.3 | 0.028 | REM | 0.612 |
| Heterozygous model | 5 | 1.32 | 1.13–1.54 | 0.000 | 15.1 | 0.318 | FEM | 0.378 |
OR, odds ratio; CI, confidence interval; REM, random-effects model; FEM, fixed-effect model.
Fig. 2.Forest plot of allele model of TLR3 (rs3775291) loci and susceptibility to HBV.
Main results of meta-analysis of HBV susceptibility to IL10 rs1800871 polymorphisms
| Genetic model | Subgroup | OR | 95% CI | I2(%) | Model | ||||
|---|---|---|---|---|---|---|---|---|---|
| Allelic model (C | Overall | 18 | 1.21 | 1.06–1.37 | 0.004 | 60.0 | 0.001 | REM | 0.133 |
| Asian | 14 | 1.16 | 1.01–1.32 | 0.031 | 56.0 | 0.006 | REM | 0.523 | |
| Caucasian and African | 4 | 1.52 | 0.99–2.32 | 0.055 | 71.9 | 0.014 | REM | 0.218 | |
| Based on HC | 15 | 1.16 | 1.02–1.31 | 0.021 | 52.7 | 0.009 | REM | 0.507 | |
| Based on S | 3 | 1.69 | 0.90–3.14 | 0.100 | 80.6 | 0.006 | REM | 0.390 | |
| Dominant model (CC + CT | Overall | 18 | 1.28 | 1.04–1.56 | 0.017 | 60.8 | 0.000 | REM | 0.205 |
| Asian | 14 | 1.22 | 0.99–1.49 | 0.056 | 61.3 | 0.001 | REM | 0.538 | |
| Caucasian and African | 4 | 1.80 | 0.81–3.97 | 0.147 | 59.7 | 0.059 | REM | 0.987 | |
| Based on HC | 15 | 1.20 | 0.99–1.47 | 0.063 | 58.8 | 0.002 | REM | 0.662 | |
| Based on S | 3 | 2.24 | 0.91–5.53 | 0.080 | 63.1 | 0.066 | REM | 0.733 | |
| Recessive model (CC | Overall | 18 | 1.20 | 1.06–1.37 | 0.005 | 33.6 | 0.082 | FEM | 0.163 |
| Asian | 14 | 1.16 | 1.00–1.34 | 0.054 | 29.5 | 0.141 | FEM | 0.458 | |
| Caucasian and African | 4 | 1.38 | 1.05–1.80 | 0.020 | 49.3 | 0.116 | FEM | 0.185 | |
| Based on HC | 15 | 1.17 | 1.02–1.35 | 0.029 | 26.0 | 0.168 | FEM | 0.437 | |
| Based on S | 3 | 1.67 | 0.85–3.27 | 0.137 | 26.0 | 0.168 | REM | 0.389 | |
| Homozygous model (CC | Overall | 18 | 1.40 | 1.07–1.83 | 0.013 | 50.6 | 0.007 | REM | 0.233 |
| Asian | 14 | 1.30 | 1.00–1.69 | 0.054 | 43.7 | 0.041 | REM | 0.595 | |
| Caucasian and African | 4 | 2.13 | 0.82–5.49 | 0.119 | 67.1 | 0.028 | REM | 0.639 | |
| Based on HC | 15 | 1.27 | 1.07–1.52 | 0.011 | 40.0 | 0.055 | FEM | 0.671 | |
| Based on S | 3 | 2.75 | 0.85–8.88 | 0.090 | 73.1 | 0.024 | REM | 0.567 | |
| Heterozygous model (CT | Overall | 18 | 1.21 | 0.99–1.47 | 0.062 | 54.9 | 0.003 | REM | 0.268 |
| Asian | 14 | 1.18 | 0.96–1.46 | 0.117 | 60.5 | 0.002 | REM | 0.448 | |
| Caucasian and African | 4 | 1.39 | 0.83–2.32 | 0.208 | 29.6 | 0.235 | FEM | 0.800 | |
| Based on HC | 15 | 1.21 | 0.99–1.47 | 0.144 | 58.5 | 0.002 | REM | 0.613 | |
| Based on S | 3 | 1.63 | 0.92–2.88 | 0.093 | 18.8 | 0.292 | REM | 0.421 |
OR, odds ratio; CI, confidence interval; REM, random-effects model; FEM, fixed-effect model; HC, healthy control; S, self-limiting infection controls.
Fig. 3.Forest plot of IL-10 (rs1800871) polymorphism and susceptibility to HBV (a: allelic genetic model; b: dominant genetic model; c: recessive genetic model; d: homozygous genetic model; e: heterozygous genetic model).
Fig. 4.Funnel plot of IL-10 (rs1800871) polymorphism and susceptibility to HBV (a: allelic genetic model; b: dominant genetic model; c: recessive genetic model; d: homozygous genetic model; e: heterozygous genetic model).
Fig. 5.Sensitivity analysis of TLR3 (rs3775291) polymorphism and susceptibility to HBV (a: allelic genetic model; b: dominant genetic model; c: recessive genetic model; d: homozygous genetic model; e: heterozygous genetic model).
Fig. 6.Sensitivity analysis of IL-10 (rs1800871) polymorphism and susceptibility to HBV (a: allelic genetic model; b: dominant genetic model; c: recessive genetic model; d: homozygous genetic model; e: heterozygous genetic model).